Associate Owners Group, Inc. (AOG) proudly announces it has acquired Common Sense Financial, a dynamic life insurance ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present the latest findings on lecanemab (generic name, U.S. brand name: LEQEMBI®), Eisai's ...

Hydrocephalus Shunts Market To Reach US$1,495.8 Mn By 2033 At 5.8% CAGR Persistence Market Research. EINPresswire/ -- The global hydrocephalus shunts market is projected to grow from US$ 910.6 million ...

TerSera Therapeutics LLC today announced that it has completed the previously announced sale of its Infusion Specialty Therapies Business Unit (IST), including two specialty medications, Prialt® ...

Les Masterson is a deputy editor and insurance analyst at Forbes Advisor. He has been a journalist, reporter, editor and content creator for more than 25 years. He has covered insurance for a decade, ...

Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with ...

Neurologists Indu Subramanian and Alfonso Fasano discuss normal pressure hydrocephalus and why some of the classic dogma about this condition is wrong.

Camp4 Therapeutics FY25 GAAP EPS missed expectations, but ended the year with a robust cash position. Check out why CAMP ...

The Morningstar Fair Value Estimate helps investors understand the long-term, intrinsic value of a stock, helping them see beyond the present market price. It represents a Morningstar analyst's ...

BioArctic's AB (publ) (STOCKHOLM: BIOA B) partner Eisai announced today that they will present the latest findings on lecanemab at the 2026 International ...